

Aristeidis I Chaidos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7876756/publications.pdf>

Version: 2024-02-01

80
papers

2,791
citations

279798

23
h-index

182427

51
g-index

82
all docs

82
docs citations

82
times ranked

5126
citing authors

#	ARTICLE	IF	CITATIONS
1	The innate sensor ZBP1-IRF3 axis regulates cell proliferation in multiple myeloma. <i>Haematologica</i> , 2022, 107, 721-732.	3.5	17
2	Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma. <i>Blood</i> , 2022, 139, 1939-1953.	1.4	15
3	Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas. <i>Blood Reviews</i> , 2022, 56, 100988.	5.7	6
4	Tocilizumab's efficacy in patients with Coronavirus Disease 2019 (COVID-19) is determined by the presence of cytokine storm. <i>Journal of Medical Virology</i> , 2021, 93, 120-121.	5.0	3
5	Masked crystalline light chain tubulopathy and podocytopathy with focal segmental glomerulosclerosis: a rare MGRS-associated renal lesion. <i>Histopathology</i> , 2021, 79, 265-268.	2.9	1
6	Single-cell profiling of human bone marrow progenitors reveals mechanisms of failing erythropoiesis in Diamond-Blackfan anemia. <i>Science Translational Medicine</i> , 2021, 13, eabf0113.	12.4	32
7	Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma. <i>Nature Communications</i> , 2021, 12, 5450.	12.8	19
8	Brd2/4 and Myc regulate alternative cell lineage programmes during early osteoclast differentiation in vitro. <i>IScience</i> , 2021, 24, 101989.	4.1	13
9	Time from first symptom onset to the final diagnosis of multiple myeloma (MM) – possible risks and future solutions: retrospective and prospective – Deutsche Studiengruppe MM (DSMM) and European Myeloma Network (EMN) analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 875-886.	1.3	12
10	Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1433-1442.	10.7	306
11	Interleukin 6 blockade treatment for severe COVID-19 in two patients with multiple myeloma. <i>British Journal of Haematology</i> , 2020, 190, e9-e11.	2.5	24
12	Single-Cell Transcriptional Landscapes of Human Bone Marrow Reveal Distinct Erythroid Phenotypes Underpinned By Genotype in Diamond-Blackfan Anemia. <i>Blood</i> , 2020, 136, 1-2.	1.4	0
13	Autologous Stem Cell Transplant for the Treatment of Type I Crystal Cryoglobulinemic Glomerulonephritis Caused by Monoclonal Gammopathy of Renal Significance (MGRS). <i>Kidney International Reports</i> , 2019, 4, 1342-1348.	0.8	6
14	Plasmacytoma-Like Posttransplant Lymphoproliferative Disease in a Disused Arteriovenous Fistula: The Importance of Histopathology. <i>Kidney International Reports</i> , 2019, 4, 749-755.	0.8	1
15	Proliferative glomerulonephritis with monoclonal Ig deposits (PGNMID): diagnostic and treatment challenges for the nephrologist!. <i>Kidney International</i> , 2019, 95, 467-468.	5.2	15
16	Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2019, 393, 253-264.	13.7	187
17	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. <i>Nature Reviews Nephrology</i> , 2019, 15, 45-59.	9.6	330
18	Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies. <i>Clinical Nutrition</i> , 2019, 38, 738-744.	5.0	37

#	ARTICLE	IF	CITATIONS
19	Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , 2019, 134, 123-123.	1.4	33
20	Myc and Bet Proteins Orchestrate the Early Regulatory Genome Changes Required for Osteoclast Lineage Commitment. <i>Blood</i> , 2019, 134, 4329-4329.	1.4	0
21	Oncogenic MAF in Co-Operation with IRF4 Confers Extensive Chromatin Re-Arrangement in Plasma Cells and Generates 'Neo-Enhancers' That Regulate Genes Critical for Myeloma Biology. <i>Blood</i> , 2019, 134, 3783-3783.	1.4	1
22	Novel ZBP1-IRF3 Dependency in Multiple Myeloma Mediated By IRF3-Driven Regulation of Cell Cycle Genes. <i>Blood</i> , 2019, 134, 2521-2521.	1.4	0
23	C-reactive protein prior to myeloablative allogeneic haematopoietic cell transplantation identifies patients at risk of early and long-term mortality. <i>British Journal of Haematology</i> , 2018, 180, 889-892.	2.5	6
24	Updated Report on Identification of Molecular Predictors of Tazemetostat Response in an Ongoing NHL Phase 2 Study. <i>Blood</i> , 2018, 132, 4097-4097.	1.4	5
25	A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Single Agent Study in Subjects with Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , 2018, 132, 1682-1682.	1.4	12
26	Incidence and Risk Factors for Second Malignancies after Transplant in Long Term Survivors of Allogeneic Haematopoietic Stem Cell Transplant: A Single Centre Experience. <i>Blood</i> , 2018, 132, 3417-3417.	1.4	0
27	Clustering Analysis of Myeloma Clone Phenotype Is Informative for Disease Heterogeneity and Prognosis at Relapse. <i>Blood</i> , 2018, 132, 4492-4492.	1.4	0
28	Interim Report from a Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor: Clinical Activity and Favorable Safety in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S380-S381.	0.4	3
29	High resolution IgH repertoire analysis reveals fetal liver as the likely origin of life-long, innate B lymphopoiesis in humans. <i>Clinical Immunology</i> , 2017, 183, 8-16.	3.2	15
30	Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation. <i>Bone Marrow Transplantation</i> , 2017, 52, 1599-1601.	2.4	14
31	The Role of Invariant NKT Cells in Immunity. , 2016, , 357-368.		0
32	Results of a multicentre <sc>UK</sc>-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2016, 173, 896-904.	2.5	19
33	Impact of Nutrition on Non-Relapse Mortality and Acute Graft Versus Host Disease during Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. <i>Blood</i> , 2016, 128, 2226-2226.	1.4	1
34	A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Subjects with Relapsed, Refractory Hematologic Malignancies. <i>Blood</i> , 2016, 128, 5223-5223.	1.4	6
35	The Intensive Care Trial for Critically Ill Onco-Haematologic Patients: The Need for Response Criteria at 5 Days of Full Treatment to Separate Good Risk Patients and Avoid Futile Intensive Care Interventions. <i>Blood</i> , 2016, 128, 5987-5987.	1.4	1
36	Preconditioning Neutropenia Is a Key Prognostic Factor in Allogeneic Hematopoietic Cell Transplantation for High Risk Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 3411-3411.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Elucidation of the EP defect in Diamond-Blackfan anemia by characterization and prospective isolation of human EPs. <i>Blood</i> , 2015, 125, 2553-2557.	1.4	33
38	Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. <i>Therapeutic Advances in Hematology</i> , 2015, 6, 128-141.	2.5	141
39	Myeloma Propagating Cells, Drug Resistance and Relapse. <i>Stem Cells</i> , 2015, 33, 3205-3211.	3.2	7
40	Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease. <i>Journal of Clinical Investigation</i> , 2015, 125, 2279-2292.	8.2	39
41	Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. <i>Blood</i> , 2014, 123, 697-705.	1.4	184
42	Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling. <i>Blood</i> , 2013, 122, 227-238.	1.4	97
43	Poly(ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma. <i>Oncogene</i> , 2013, 32, 4231-4242.	5.9	104
44	Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. <i>Blood</i> , 2013, 121, 318-328.	1.4	112
45	Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation. <i>Leukemia and Lymphoma</i> , 2013, 54, 2200-2204.	1.3	39
46	Combined Inhibition of p97 and the Proteasome Causes Lethal Disruption of the Secretory Apparatus in Multiple Myeloma Cells. <i>PLoS ONE</i> , 2013, 8, e74415.	2.5	45
47	Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2013, 121, 2753-2761.	1.4	81
48	Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 17579-17584.	7.1	138
49	Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. <i>Blood</i> , 2012, 119, 5030-5036.	1.4	129
50	Gene-Selective Histone Hyperacetylation and Enhanced Sp1 Occupancy Underpin Transcriptional Modulation of Genes of the Glycolytic-Pentose Phosphate Pathway in Response to Histone Deacetylase Inhibitors - Therapeutic Implications. <i>Blood</i> , 2012, 120, 977-977.	1.4	1
51	The Role of Invariant NKT Cells in Allogeneic Hematopoietic Stem Cell Transplantation. <i>Critical Reviews in Immunology</i> , 2012, 32, 157-171.	0.5	9
52	Contrasting Effects of Enhanced Sirt1 Activity in Normal and BCR-ABL1-Dependent Haematopoiesis. <i>Blood</i> , 2012, 120, 1215-1215.	1.4	0
53	Autoreactive T Cells From Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Specifically Recognize Glycosyl- Phosphatidyl-Inositol (GPI). <i>Blood</i> , 2012, 120, 647-647.	1.4	6
54	Cryopreserved Allogeneic Peripheral Blood Stem Cells Result in Outcome Equivalent to Those of Fresh Infusions Enabling Rational Scheduling of Donations,. <i>Blood</i> , 2011, 118, 4052-4052.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor Have Normal T Cell Responses to Vaccination but An Impaired IgM Humoral Response Associated with Loss of Discrete Memory B Cell Subsets.. <i>Blood</i> , 2011, 118, 3753-3753.	1.4	0
56	Elevated Preconditioning Serum Levels of C-Reactive Protein Are Associated with Increased Nonrelapse Mortality and Inferior Survival After Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2011, 118, 1945-1945.	1.4	0
57	High Frequency and Cell Dose of Invariant NKT Cells In the Graft Are Associated with Lack of Clinically Significant Acute Gvhd In T Cell-Replete Sibling Allografts. <i>Blood</i> , 2010, 116, 2539-2539.	1.4	1
58	Trilineage Perturbation of Hematopoiesis In Neonates with Down Syndrome. <i>Blood</i> , 2010, 116, 876-876.	1.4	1
59	Second Autologous Stem Cell Transplantation Is Effective Salvage Therapy for Relapsed Multiple Myeloma.. <i>Blood</i> , 2009, 114, 1229-1229.	1.4	2
60	Glucose Ceramide Synthase Inhibitors Inhibit Osteoclast Activation Induced by Myeloma-Derived and De Novo Synthesized Glycosphingolipids.. <i>Blood</i> , 2009, 114, 424-424.	1.4	2
61	Successful peripheral blood stem cell mobilization with granulocyte colony-stimulating factor in a patient with chronic myeloid leukemia achieving a complete cytogenetic remission with dasatinib after failing imatinib. <i>Leukemia</i> , 2008, 22, 1618-1619.	7.2	1
62	Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis. <i>British Journal of Haematology</i> , 2008, 141, 745-747.	2.5	132
63	Human Invariant NKT Cells Display Alloreactivity Instructed by Invariant TCR-CD1d Interaction and Killer Ig Receptors. <i>Journal of Immunology</i> , 2008, 181, 3268-3276.	0.8	23
64	A long-term durable remission with high-dose therapy and autologous stem cell transplant for stage IVB HIV-associated Hodgkins disease. <i>Aids</i> , 2008, 22, 539-540.	2.2	4
65	Recombinant Human Erythropoietin for the Treatment of Anaemia in Patients with Chronic Idiopathic Myelofibrosis. <i>Acta Haematologica</i> , 2007, 117, 156-161.	1.4	38
66	Risk assessment in haematopoietic stem cell transplantation: Disease and disease stage. <i>Best Practice and Research in Clinical Haematology</i> , 2007, 20, 125-154.	1.7	25
67	LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. <i>Bone Marrow Transplantation</i> , 2007, 39, 41-47.	2.4	27
68	Non-secretory multiple myeloma with involvement of the hand as initial manifestation. <i>Leukemia and Lymphoma</i> , 2006, 47, 1677-1679.	1.3	1
69	Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis. <i>European Journal of Haematology</i> , 2005, 74, 273-274.	2.2	11
70	Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2005, 11, 272-275.	3.0	70
71	Beneficial Effect of Rituximab in Combination with Oral Cyclophosphamide in Primary Chronic Cold Agglutinin Disease. <i>International Journal of Hematology</i> , 2005, 81, 421-423.	1.6	9
72	Treatment of Resistant/Relapsing Chronic Lymphocytic Leukemia with a Combination Regimen Containing Deoxycoformycin and Rituximab. <i>Acta Haematologica</i> , 2004, 111, 185-188.	1.4	7

#	ARTICLE	IF	CITATIONS
73	Treatment of β^2 -Thalassemia Patients with Recombinant Human Erythropoietin: Effect on Transfusion Requirements and Soluble Adhesion Molecules. <i>Acta Haematologica</i> , 2004, 111, 189-195.	1.4	22
74	Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. <i>The Hematology Journal</i> , 2004, 5, 475-479.	1.4	45
75	Fatal meningitis due to <i>Listeria monocytogenes</i> in elderly patients with underlying malignancy. <i>International Journal of Clinical Practice</i> , 2004, 58, 292-296.	1.7	12
76	Antierythropoietin antibodies in thalassemia patients. <i>Annals of Hematology</i> , 2004, 83, 22-27.	1.8	6
77	Distribution and frequency of β^2 -thalassemia mutations in northwestern and central Greece. <i>European Journal of Haematology</i> , 2003, 70, 75-78.	2.2	22
78	Thalidomide Administration for the Treatment of Resistant Plasma Cell Leukemia. <i>Acta Haematologica</i> , 2003, 109, 153-155.	1.4	7
79	Incidence of apoptosis and cell proliferation in multiple myeloma. Correlation with bcl-2 protein expression and serum levels of interleukin-6 (IL-6) and soluble IL-6 receptor. <i>European Journal of Haematology</i> , 2002, 69, 90-94.	2.2	5
80	Recombinant human erythropoietin for the treatment of anemia in chronic myelogenous leukemia. <i>European Journal of Haematology</i> , 1997, 59, 263-265.	2.2	4